KMDA vs PACB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
KMDA presents a dichotomy between a fortress-like balance sheet and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health and the Debt/Equity ratio (0.04) is exceptionally low, the stock trades at a significant premium to its Graham Number ($6.06) and Intrinsic Value ($2.45). The attractive PEG ratio (0.63) suggests growth is undervalued, but this is offset by negative YoY earnings growth (-14.10%) and a bearish technical trend.
PACB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and an operating margin of -134.54%. While the company maintains a strong current ratio (5.15) and modest revenue growth (13.8%), these are overshadowed by a catastrophic 5-year price decline of 94.5% and an extreme Price-to-Book ratio of 90.56. There is a stark divergence between the analyst 'Buy' consensus and the bearish insider activity, with the CEO, CFO, and COO all selling shares. The company is currently in a high-risk survival phase with no clear path to profitability.
Compare Another Pair
Related Comparisons
KMDA vs PACB: Head-to-Head Comparison
This page compares Kamada Ltd. (KMDA) and Pacific Biosciences of California, Inc. (PACB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.